Agenus Inc. (NASDAQ:AGEN) insider Christine M. Klaskin sold 11,120 shares of Agenus stock in a transaction on Friday, September 10th. The shares were sold at an average price of $6.50, for a total transaction of $72,280.00. The sale was disclosed in a document filed with the SEC, which is available through this link.
NASDAQ:AGEN opened at $5.59 on Wednesday. The firm has a market capitalization of $1.30 billion, a PE ratio of -4.99 and a beta of 1.35. Agenus Inc. has a 1 year low of $2.50 and a 1 year high of $6.79. The firm’s fifty day simple moving average is $5.80 and its 200 day simple moving average is $4.45.
Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Sunday, August 8th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.13). Equities analysts anticipate that Agenus Inc. will post -0.28 EPS for the current fiscal year.
AGEN has been the subject of a number of recent research reports. B. Riley upped their price objective on shares of Agenus from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, September 7th. Zacks Investment Research downgraded Agenus from a “buy” rating to a “hold” rating in a research note on Tuesday, August 10th.
Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K.
Featured Story: Is it Safe to Invest in Commodities?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.